title: A single dose of intravenous esomeprazole decreases gastric secretion in healthy volunteers.
abstract: BACKGROUND
  Data suggest that esomeprazole decreases gastric secretion.
  
  
  OBJECTIVE
  To assess the effect of a single i.v. esomeprazole dose on gastric secretion volume 3 h after drug administration, as a primary endpoint, and to evaluate, as secondary endpoints, the reduction 1 and 5 h after dosing; time when the gastric pH was <2.5 and esomeprazole's safety.
  
  
  METHODS
  In all, 23 healthy Helicobacter pylori-negative volunteers (10 men, 13 women, mean age 28.2 +/- 6) participated in this single-centre, randomized, double-blind, placebo-controlled, 2-way, single-dose cross-over study. In different sessions, volunteers received i.v. either esomeprazole 40 mg or placebo. An inserted double-lumen nasogastric tube perfused and aspirated gastric liquid. Mechanical fractioned aspiration measured secretion volume; aliquot spectrophotometry assessed gastric secretion volume lost to the duodenum.
  
  
  RESULTS
  Three hours post-i.v. esomeprazole, average gastric secretion decreased by 77.6% (vs. baseline) compared to placebo. Values 1 and 5 h after dosing were 73.5% and 74.5%. Five hours after esomeprazole, the gastric pH was <2.5 3.9% of the time and 73.3% after placebo (P < 0.002). Esomeprazole was well-tolerated. No serious adverse events occurred.
  
  
  CONCLUSIONS
  Intravenous esomeprazole decreases gastric secretions. The potential clinical impact in averting bronchoaspiration during anaesthesia induction and in intensive care patients should be investigated in further studies.
authors.affiliation: Department of Gastroenterology and Hepatology at the University Hospital in Lausanne, Switzerland. cristina.nichita@chuv.ch
authors.forename: C
authors.initials: C
authors.lastname: Nichita
authors.forename: A E-W
authors.initials: AE
authors.lastname: Abdou
authors.forename: P
authors.initials: P
authors.lastname: Maerten
authors.forename: M
authors.initials: M
authors.lastname: Herranz
authors.forename: N
authors.initials: N
authors.lastname: Mouret
authors.forename: C
authors.initials: C
authors.lastname: Thalmann
authors.forename: P F
authors.initials: PF
authors.lastname: Michetti
authors.forename: G
authors.initials: G
authors.lastname: Dorta
mesh_terms: D000293:Adolescent; D000328:Adult; D000897:Anti-Ulcer Agents / Q000008:administration & dosage* / Q000494:pharmacology; D018592:Cross-Over Studies; D004311:Double-Blind Method; D064098:Esomeprazole / Q000008:administration & dosage* / Q000494:pharmacology; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D006801:Humans; D006863:Hydrogen-Ion Concentration / Q000187:drug effects*; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D054328:Proton Pump Inhibitors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D064098:Esomeprazole